116 reports of this reaction
1.5% of all NORGESTIMATE AND ETHINYL ESTRADIOL reports
#14 most reported adverse reaction
PRODUCT SUBSTITUTION ISSUE is the #14 most commonly reported adverse reaction for NORGESTIMATE AND ETHINYL ESTRADIOL, manufactured by Teva Pharmaceuticals USA, Inc.. There are 116 FDA adverse event reports linking NORGESTIMATE AND ETHINYL ESTRADIOL to PRODUCT SUBSTITUTION ISSUE. This represents approximately 1.5% of all 7,959 adverse event reports for this drug.
Patients taking NORGESTIMATE AND ETHINYL ESTRADIOL who experience product substitution issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT SUBSTITUTION ISSUE is a less commonly reported adverse event for NORGESTIMATE AND ETHINYL ESTRADIOL, but still significant enough to appear in the safety profile.
In addition to product substitution issue, the following adverse reactions have been reported for NORGESTIMATE AND ETHINYL ESTRADIOL:
The following drugs have also been linked to product substitution issue in FDA adverse event reports:
PRODUCT SUBSTITUTION ISSUE has been reported as an adverse event in 116 FDA reports for NORGESTIMATE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT SUBSTITUTION ISSUE accounts for approximately 1.5% of all adverse event reports for NORGESTIMATE AND ETHINYL ESTRADIOL, making it a notable side effect.
If you experience product substitution issue while taking NORGESTIMATE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.